Nicox S.A. (NICXF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -17.5 Million EUR | 44.09% |
| 2022 | -35.39 Million USD | 33.24% |
| 2021 | -53.01 Million USD | -459.08% |
| 2020 | -9.48 Million USD | 56.04% |
| 2019 | -21.57 Million USD | -4.37% |
| 2018 | -20.66 Million EUR | -11.61% |
| 2017 | -18.51 Million EUR | -137.9% |
| 2016 | -7.78 Million EUR | 62.44% |
| 2015 | -20.72 Million EUR | 3.91% |
| 2014 | -21.56 Million EUR | -96.01% |
| 2013 | -11 Million EUR | -25.79% |
| 2012 | -8.74 Million EUR | 50.39% |
| 2011 | -17.63 Million EUR | 59.93% |
| 2010 | -43.99 Million EUR | 29.02% |
| 2009 | -61.98 Million EUR | 21.75% |
| 2008 | -79.21 Million EUR | -112.95% |
| 2007 | -37.19 Million EUR | -39.54% |
| 2006 | -26.65 Million EUR | -63.19% |
| 2005 | -16.33 Million EUR | -11.99% |
| 2004 | -14.58 Million EUR | 25.53% |
| 2003 | -19.58 Million EUR | -4.45% |
| 2002 | -18.75 Million EUR | -19.66% |
| 2001 | -15.67 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -19.78 Million EUR | 44.09% |
| 2023 Q2 | -8.46 Million USD | -84.79% |
| 2023 Q1 | -4.58 Million EUR | 63.42% |
| 2022 Q1 | -6.04 Million EUR | 82.29% |
| 2022 Q2 | -20.54 Million USD | -240.07% |
| 2022 Q3 | -5.29 Million EUR | 74.21% |
| 2022 Q4 | -12.52 Million USD | -136.43% |
| 2022 FY | -35.39 Million USD | 33.24% |
| 2021 Q2 | -12.52 Million EUR | -75.56% |
| 2021 Q3 | -3.43 Million EUR | 72.62% |
| 2021 Q4 | -34.11 Million EUR | -894.4% |
| 2021 FY | -53.01 Million USD | -459.08% |
| 2021 Q1 | -7.13 Million EUR | -1411.76% |
| 2020 FY | -9.48 Million USD | 56.04% |
| 2020 Q4 | 544 Thousand EUR | 8.14% |
| 2020 Q3 | 503.04 Thousand EUR | 106.07% |
| 2020 Q1 | -4.27 Million EUR | 68.4% |
| 2020 Q2 | -8.29 Million EUR | -93.99% |
| 2019 FY | -21.57 Million USD | -4.37% |
| 2019 Q4 | -13.53 Million EUR | -91.49% |
| 2019 Q3 | -7.06 Million EUR | -134.0% |
| 2019 Q1 | -2.97 Million EUR | 57.22% |
| 2019 Q2 | -3.01 Million EUR | -1.38% |
| 2018 Q3 | -7.05 Million EUR | -33.04% |
| 2018 Q2 | -5.3 Million EUR | 5.21% |
| 2018 FY | -20.66 Million EUR | -11.61% |
| 2018 Q4 | -6.96 Million EUR | 1.32% |
| 2018 Q1 | -5.59 Million EUR | 0.0% |
| 2017 Q1 | -5.25 Million EUR | -13.56% |
| 2017 Q2 | -5.62 Million EUR | -7.06% |
| 2017 FY | -18.51 Million EUR | -137.9% |
| 2016 Q4 | -4.62 Million EUR | 6.3% |
| 2016 Q2 | -6.49 Million EUR | 2.49% |
| 2016 Q1 | -6.66 Million EUR | -57.75% |
| 2016 Q3 | -4.93 Million EUR | 24.01% |
| 2016 FY | -7.78 Million EUR | 62.44% |
| 2015 Q4 | -4.22 Million EUR | 2.68% |
| 2015 FY | -20.72 Million EUR | 3.91% |
| 2015 Q3 | -4.34 Million EUR | 5.65% |
| 2015 Q2 | -4.6 Million EUR | -3.69% |
| 2015 Q1 | -4.43 Million EUR | 0.0% |
| 2014 FY | -21.56 Million EUR | -96.01% |
| 2014 Q2 | -7.27 Million EUR | 0.64% |
| 2014 Q1 | -7.32 Million EUR | -81.7% |
| 2013 Q4 | -4.03 Million EUR | 6.08% |
| 2013 FY | -11 Million EUR | -25.79% |
| 2013 Q3 | -4.29 Million EUR | -187.43% |
| 2013 Q2 | 4.91 Million EUR | 13.11% |
| 2013 Q1 | 4.34 Million EUR | 191.16% |
| 2012 FY | -8.74 Million EUR | 50.39% |
| 2012 Q3 | -3.53 Million EUR | 21.4% |
| 2012 Q4 | -4.76 Million EUR | -34.79% |
| 2012 Q1 | 4.04 Million EUR | 160.33% |
| 2012 Q2 | -4.49 Million EUR | -211.18% |
| 2011 FY | -17.63 Million EUR | 59.93% |
| 2011 Q3 | -2.77 Million EUR | 30.36% |
| 2011 Q1 | -4.16 Million EUR | 33.37% |
| 2011 Q2 | -3.98 Million EUR | 4.41% |
| 2011 Q4 | -6.7 Million EUR | -141.48% |
| 2010 Q3 | -10.38 Million EUR | 48.96% |
| 2010 Q1 | -7.01 Million EUR | 0.0% |
| 2010 FY | -43.99 Million EUR | 29.02% |
| 2010 Q4 | -6.25 Million EUR | 39.74% |
| 2010 Q2 | -20.34 Million EUR | -190.13% |
| 2009 Q1 | -12 Million EUR | 0.0% |
| 2009 FY | -61.98 Million EUR | 21.75% |
| 2008 FY | -79.21 Million EUR | -112.95% |
| 2007 FY | -37.19 Million EUR | -39.54% |
| 2006 FY | -26.65 Million EUR | -63.19% |
| 2005 FY | -16.33 Million EUR | -11.99% |
| 2004 FY | -14.58 Million EUR | 25.53% |
| 2003 FY | -19.58 Million EUR | -4.45% |
| 2002 FY | -18.75 Million EUR | -19.66% |
| 2001 FY | -15.67 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 75.618% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 456.128% |
| SQZ Biotechnologies Company | -75.82 Million USD | 76.917% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 1.927% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 121.384% |
| Mesoblast Limited | -84.14 Million USD | 79.199% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1039.482% |
| Genus plc | 6.4 Million USD | 373.484% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 279.657% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1779.254% |
| Marizyme, Inc. | -34.08 Million USD | 48.651% |
| ContraFect Corporation | -56.88 Million USD | 69.233% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -109.617% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -284.282% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1148.439% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -514.031% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -536.279% |
| MultiCell Technologies, Inc. | -722.81 USD | -2421421.562% |
| Accustem Sciences Inc. | -3.74 Million USD | -367.193% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 70.329% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3523.344% |
| Q BioMed Inc. | -3.44 Million USD | -407.979% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 594.435% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -4392.902% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -566.141% |
| Biomind Labs Inc. | -1 Million USD | -1633.652% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -258.702% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -163.282% |
| Skye Bioscience, Inc. | -13.67 Million USD | -28.023% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -781.107% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -58336.832% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -246.973% |
| IMV Inc. | -38.67 Million USD | 54.739% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -10.292% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -805.666% |
| GB Sciences, Inc. | -1.42 Million USD | -1132.164% |
| Alpha Cognition Inc. | -9.7 Million USD | -80.339% |
| HST Global, Inc. | -140.9 Thousand USD | -12321.668% |
| CSL Limited | 3.7 Billion USD | 100.473% |
| Halberd Corporation | -75.05 Thousand USD | -23221.785% |
| Enzolytics Inc. | -2.14 Million USD | -714.548% |
| Resverlogix Corp. | -12.74 Million USD | -37.289% |
| Affymax, Inc. | -15.04 Million USD | -16.33% |
| SYBLEU INC | -149.18 Thousand USD | -11632.806% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -452.446% |
| argenx SE | -425.04 Million USD | 95.882% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 68.468% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1576.533% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1008.237% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -414.041% |
| AVAX Technologies, Inc. | 6.69 Million USD | 361.517% |
| Zenith Capital Corp. | -8.94 Million USD | -95.717% |
| Genscript Biotech Corporation | -415.79 Million USD | 95.79% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -100370.696% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -612.861% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -10105.263% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 68.16% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -503.292% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1678.664% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -838.816% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1293.551% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -773.073% |
| BioStem Technologies, Inc. | -7.77 Million USD | -125.004% |
| ONE Bio Corp. | 13.68 Million USD | 227.931% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -9544.323% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1210.663% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1455.952% |
| Agentix Corp. | -1.37 Million USD | -1175.956% |
| LadRx Corporation | -3.82 Million USD | -357.759% |
| Cell Source, Inc. | -4.32 Million USD | -304.661% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4112.728% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2447.929% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2447.929% |
| NovAccess Global Inc. | -2.46 Million USD | -609.554% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -499.532% |
| Itoco Inc. | -919.14 Thousand USD | -1804.28% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -312.961% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1464.164% |
| Kadimastem Ltd | -3.04 Million USD | -475.709% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -6587.528% |
| CytoDyn Inc. | -18.05 Million USD | 3.073% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -69439.134% |
| Mobile Lads Corp. | -554.55 Thousand USD | -3056.253% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -7853.089% |
| Qrons Inc. | -643.67 Thousand USD | -2619.221% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2999.396% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -684.93% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2535.994% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -863.652% |
| International Stem Cell Corporation | -663 Thousand USD | -2539.97% |
| Bioxytran, Inc. | -3.82 Million USD | -358.176% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -33150.38% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -85952.114% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 51.737% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -981.768% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2278.658% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -462.617% |
| Neutra Corp. | -229.48 Thousand USD | -7527.045% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 0.205% |
| PureTech Health plc | -146.19 Million USD | 88.028% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 18.557% |
| IXICO plc | -1.43 Million USD | -1118.024% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -84.417% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 85.63% |
| CSL Limited | 3.81 Billion USD | 100.459% |
| Cellectis S.A. | -108.85 Million USD | 83.921% |